Stock Taper
CING
CINGULATE INC.
NASDAQ
$5.33
▼ DOWN 2.11% (-0.12)

KEY STATISTICS

Market Cap$71.72 M
52w High$11.89
52w Low$3.16
Dividend Yield
Frequency
P/E-1.48
Volume108.41K
Shares Out.13.47M

COMPANY

LEADERSHIP

Shane J. Schaffer
CHIEF EXECUTIVE
Shane J. Schaffer

COMPENSATION 2026

Salary$319,281
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$770,327

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 8, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
14

PRICE TARGET

Target High$9.00
Target Low$9.00
Target Median$9.00
Target Consensus$9.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$540.00K
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2024-08-09Reverse1:12
2023-11-30Reverse1:20

PRICE

$5.33 ▼ DOWN 2.11% (−$0.12)
OVERLAYS
$5.33$5.40$5.489:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.33

About Cingulate Inc.

https://www.cingulate.com ↗

Cingulate Inc. is a clinical-stage biopharmaceutical company developing treatments for ADHD and anxiety, with lead candidates CTx-1301 (phase 3) and CTx-1302, based in Kansas City, Kansas.

INDUSTRY

Biotechnology

A PRODUCT CINGULATE INC. IS KNOWN FOR

CTx-1301
CTx-1301

CTx-1301 is a late-stage, once-daily ADHD treatment by Cingulate, utilizing their proprietary PTR™ platform, with an FDA-submitted NDA, offering fast onset and all-day efficacy.

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

OFFICER: EVP AND CFO
Callahan Jennifer L.
Purchase · 40.2K shares
2026-07-16
OFFICER: EVP & CHIEF COMMERCIAL OFFICER
Downey Bryan Wade
Purchase · 67.0K shares
2026-07-16
DIRECTOR
Hargroves Thomas Jeffrey
Purchase · 20.0K shares
2026-07-16
OFFICER: EVP AND CFO
Callahan Jennifer L.
Purchase · 19.8K shares
2026-07-16

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
3 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
BCTX$3.73COMPARE
ALLR$1.41COMPARE
LEXX$10.35COMPARE
SYBX$1.22COMPARE
NCNA$1.76COMPARE